It is therefore unsurprising to find increased cancer risks amongst LRRK2-G2019S PD patients in our study, with LRRK2 promoting PD-associated neurodegeneration and cancer-related pathogenesis pathways. This evidence concerns the gene LRRK2 and Parkinson disease.